GSK: £2 BILLION SHARE BUYBACK PROGRAMME TO BE IMPLEMENTED OVER NEXT 18 MONTHS
GSK Q4 TURNOVER 8,117 MILLION POUNDS VERSUS IBES ESTIMATE 7,750 MILLION POUNDS
GSK: 2031 SALES OUTLOOK INCREASED TO MORE THAN £40 BILLION
GSK Q4 ADJUSTED EPS 23.2 P VERSUS IBES ESTIMATE 19.01 P
GSK: SALES OF MORE THAN £40 BILLION NOW EXPECTED BY 2031
GSK OUTLOOK 2025 VACCINES EXPECTED DECREASE OF A LOW SINGLE-DIGIT PER CENT IN TURNOVER
GSK: INCREASING AND PRIORITISING RESEARCH AND DEVELOPMENT INVESTMENT TO PROMISING NEW LONG-ACTING AND SPECIALTY MEDICINES
GSK - DIVIDEND 64P EXPECTED FOR 2025
Source text: ID:nRSE9111Va
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.